

## SEQUENCE LISTING

<110> Clinton, Gail M.  
Evans, Adam  
Henner, William D.

<120> HER-2 BINDING ANTAGONISTS

<130> 49321-16

<140> US 09/506,079

<141> 2000-02-16

<150> US 09/234,208

<151> 1999-01-20

<160> 10

<210> 1

<211> 79

<212> PRT

<213> Homo Sapiens

<220>

<221> Variable

<222> 2

<223> Applicants herein disclose Thr and Ser sequence variants at this position

<220>

<221> Variable

<222> 5

<223> Applicants herein disclose Leu and Pro sequence variants at this position

<220>

<221> Variable

<222> 6

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> Variable

<222> 16

<223> Applicants herein disclose Leu and Gln sequence variants at this position

<220>

<221> Variable

<222> 18

<223> Applicants herein disclose Met and Leu sequence variants at this position

<220>

<221> Variable

<222> 21

<223> Applicants herein disclose Gly, Asp, Ala and Val sequence variants at this position

<220>

<221> Variable

<222> 36

Best Available Copy

<223> Applicants herein disclose Leu and Ile sequence variants at this position

<220>

<221> Variable

<222> 54

<223> Applicants herein disclose Pro and Arg sequence variants at this position

<220>

<221> Variable

<222> 64

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> Variable

<222> 73

<223> Applicants herein disclose Asp and Asn sequence variants at this position

<400> 1

Gly	Xaa	His	Ser	Xaa	Xaa	Pro	Arg	Pro	Ala	Ala	Val	Pro	Val	Pro	Xaa
				5					10					15	
Arg	Xaa	Gln	Pro	Xaa	Pro	Ala	His	Pro	Val	Leu	Ser	Phe	Leu	Arg	Pro
			20					25					30		
Ser	Trp	Asp	Xaa	Val	Ser	Ala	Phe	Tyr	Ser	Leu	Pro	Leu	Ala	Pro	Leu
		35					40					45			
Ser	Pro	Thr	Ser	Val	Xaa	Ile	Ser	Pro	Val	Ser	Val	Gly	Arg	Gly	Xaa
	50					55					60				
Asp	Pro	Asp	Ala	His	Val	Ala	Val	Xaa	Leu	Ser	Arg	Tyr	Glu	Gly	
65					70					75					

<210> 2

<211> 419

<212> PRT

<213> Homo Sapiens

<220>

<221> Variable

<222> 342

<223> Applicants herein disclose Thr and Ser sequence variants at this position

<220>

<221> Variable

<222> 345

<223> Applicants herein disclose Leu and Pro sequence variants at this position

<220>

<221> Variable

<222> 346

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> Variable

<222> 356

<223> Applicants herein disclose Leu and Gln sequence variants at

this position

<220>

<221> Variable

<222> 358

<223> Applicants herein disclose Met and Leu sequence variants at this position

<220>

<221> Variable

<222> 361

<223> Applicants herein disclose Gly, Asp, Ala and Val sequence variants at this position

<220>

<221> Variable

<222> 376

<223> Applicants herein disclose Leu and Ile sequence variants at this position

<220>

<221> Variable

<222> 394

<223> Applicants herein disclose Pro and Arg sequence variants at this position

<220>

<221> Variable

<222> 404

<223> Applicants herein disclose Pro and Leu sequence variants at this position

<220>

<221> Variable

<222> 413

<223> Applicants herein disclose Asp and Asn sequence variants at this position

<400> 2

Met	Glu	Leu	Ala	Ala	Leu	Cys	Arg	Trp	Gly	Leu	Leu	Leu	Ala	Leu	Leu	
				5					10					15		
Pro	Pro	Gly	Ala	Ala	Ser	Thr	Gln	Val	Cys	Thr	Gly	Thr	Asp	Cys	Lys	
			20					25					30			
Leu	Arg	Leu	Pro	Ala	Ser	Pro	Glu	Thr	His	Leu	Asp	Met	Leu	Arg	His	
		35					40				45					
Leu	Tyr	Gln	Gly	Cys	Gln	Val	Val	Gln	Gly	Asn	Leu	Glu	Leu	Thr	Tyr	
	50					55				60						
Leu	Pro	Thr	Asn	Ala	Ser	Leu	Ser	Phe	Leu	Gln	Asp	Ile	Gln	Glu	Val	
	65				70				75						80	
Gln	Gly	Tyr	Val	Leu	Cys	Ala	His	Asn	Gln	Val	Arg	Gln	Val	Pro	Leu	
			85					90						95		
Gln	Arg	Leu	Arg	Ile	Val	Arg	Gly	Thr	Gln	Leu	Phe	Glu	Asp	Asn	Tyr	
			100					105					110			
Ala	Leu	Ala	Val	Leu	Asp	Asn	Gly	Asp	Pro	Leu	Arg	Arg	Thr	Thr	Pro	
		115					120					125				
Val	Thr	Gly	Ala	Ser	Pro	Gly	Gly	Leu	Arg	Glu	Leu	Gln	Leu	Arg	Ser	
	130					135					140					
Leu	Thr	Glu	Cys	Leu	Lys	Gly	Gly	Val	Leu	Ile	Gln	Arg	Asn	Pro	Gln	
	145				150				155						160	
Leu	Cys	Tyr	Gln	Asp	Thr	Ile	Leu	Trp	Lys	Asp	Ile	Phe	His	Lys	Asn	

3

Best Available Copy

```

          165          170          175
Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
          180          185          190
His Pro Cys Ser Pro Cys Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
          195          200          205
Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
          210          215          220
Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
          225          230          235
Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
          245          250          255
His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
          260          265          270
Thr Tyr Asn Thr Asp Thr Phe Glu Ser Cys Pro Asn Pro Glu Gly Arg
          275          280          285
Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Lys Leu
          290          295          300
Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
          305          310          315
Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
          325          330          335
Pro Cys Ala Arg Gly Xaa His Ser Xaa Xaa Pro Arg Pro Ala Val
          340          345          350
Pro Val Pro Xaa Arg Xaa Gln Pro Xaa Pro Ala His Pro Val Leu Ser
          355          360          365
Phe Leu Arg Pro Ser Trp Asp Xaa Val Ser Ala Phe Tyr Ser Leu Pro
          370          375          380
Leu Ala Pro Leu Asp Pro Thr Ser Val Xaa Ile Ser Pro Val Ser Val
          385          390          395
Gly Arg Gly Xaa Asp Pro Asp Ala His Val Ala Val Xaa Leu Ser Arg
          405          410          415
Tyr Glu Gly

```

&lt;210&gt; 3

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER-2-specific oligonucleotide primer

&lt;400&gt; 3

tgagcaccat ggagctggc 19

&lt;210&gt; 4

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; HER-2-specific oligonucleotide primer

&lt;400&gt; 4

tccggcagaa atgccaggct cc 22

&lt;210&gt; 5

<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 cDNA-specific oligonucleotide primer

<400> 5  
aacacagcgg tgtgagaagt gc 22

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 6  
ataccgggac aggtcaacag c 21

<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 ECDIIIa-region-specific oligonucleotide primer

<400> 7  
tctgggtacc cactcactgc 20

<210> 8  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 exon-specific oligonucleotide primer

<400> 8  
ttcacactgg cacgtccaga cc 22

<210> 9  
<211> 27  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> HER-2 cDNA-specific oligonucleotide primer

<400> 9  
gcacggatcc atagcagact gaggagg 27

<210> 10  
<211> 240  
<212> DNA  
<213> Homo Sapiens  
<220>

&lt;221&gt; Variable

&lt;222&gt; 62

&lt;223&gt; Applicants disclose C, T, A and G variants at this position

&lt;400&gt; 10

ggt	wcc	cac	tca	cyg	cyc	ccg	agg	cca	gct	gca	gtt	cct	gtc	cct	45
Gly	Xaa	His	Ser	Xaa	Xaa	Pro	Arg	Pro	Ala	Ala	Val	Pro	Val	Pro	
				5					10					15	

cwg	cgc	atr	cag	cct	gnc	cca	gcc	cac	cct	gtc	cta	tcc	ttc	ctc	90
Xaa	Arg	Xaa	Gln	Pro	Xaa	Pro	Ala	His	Pro	Val	Leu	Ser	Phe	Leu	
				20					25					30	

aga	ccc	tct	tgg	gac	mta	gtc	tct	gcc	ttc	tac	tct	cta	ccc	ctg	135
Arg	Pro	Ser	Trp	Asp	Xaa	Val	Ser	Ala	Phe	Tyr	Ser	Leu	Pro	Leu	
				35					40					45	

gcc	ccc	ctc	agc	cct	aca	agt	gtc	cst	ata	tcc	cct	gtc	agt	gtg	180
Ala	Pro	Leu	Ser	Pro	Thr	Ser	Val	Xaa	Ile	Ser	Pro	Val	Ser	Val	
				50					55					60	

ggg	agg	ggc	cyg	gac	cct	gat	gct	cat	gtg	gct	gtt	sac	ctg	tcc	225
Gly	Arg	Gly	Xaa	Asp	Pro	Asp	Ala	His	Val	Ala	Val	Xaa	Leu	Ser	
				65					70					75	

cgg	tat	gaa	ggc	tga											240
Arg	Tyr	Glu	Gly												